Are CROs Losing Relevance in the Age of DCTs?

In this episode, Isaac Rodriguez- Chavez and I discuss the impact of DCTs on sponsor relationships, CROs, and industry dynamics with the FDA. We discuss,1. How will DCTs impact sponsor relationships with CROs? 2. How do small CROs and sponsors adapt to emerging trends? 3. How do new trends impact industry relationships with the FDA?4. Does DCT allows the FDA to advise sponsors? 5. What is the role of technology in DCTs? 6. How do DCTs reduce the cost of bringing drugs to the market? 7.  What are the risks and advantages of DCTs? 8. What are the initial risks of DCTs? 9.  Does the FDA even have jurisdiction over patient privacy? Support the show

There are no comments yet.

Please log in to write the first comment.